News

Introducing Veeva AI Agents: Revolutionizing Life Sciences

Introducing Veeva AI Agents: Revolutionizing Life Sciences

Unlocking the Power of Veeva AI Agents in Life Sciences

Veeva AI delivers industry-specific AI for the next chapter in life sciences.

In a significant advancement for the life sciences sector, Veeva Systems (NYSE: VEEV) has introduced Veeva AI Agents designed to elevate productivity and improve customer engagement. This innovative technology is specifically tailored for the unique needs of the life sciences industry, bringing forth practical AI solutions that deliver clear business value.

Veeva AI Agents are now available for Vault CRM and PromoMats, with additional developments expected throughout the upcoming year, showcasing Veeva's commitment to enhancing operational efficiencies.

Key Features of Veeva AI for Vault CRM

The integration of Veeva AI into Vault CRM empowers teams to work smarter and more efficiently. Here are some standout features of these AI Agents:

  • Free Text Agent: This tool enhances the accuracy of call notes by detecting and flagging potential compliance issues, ensuring that the data collected is both reliable and informative. This ultimately results in richer insights into customer interactions.
  • Voice Agent: Designed for field teams, this agent allows for voice input, making it easier and faster to log information and follow-up tasks. This feature minimizes administrative burdens, letting agents focus more on customer engagement.
  • Pre-call Agent: This invaluable tool assists field representatives by providing insights and suggested actions based on relevant data. It enables reps to prepare effectively for meetings, enhancing their interactions with clients.

Innovations in Veeva AI for PromoMats

Veeva AI also plays a critical role in the management of content through PromoMats. The following agents are available:

  • Quick Check Agent: This agent scans submissions against editorial, brand, and compliance guidelines, identifying potential issues well before the content reaches the medical, legal, and regulatory (MLR) review stages.
  • Content Agent: This advanced tool offers context-aware insights into documents, aiding in questions, summarization, and visual analyses. It streamlines the review process and enhances the overall quality of content.

Seamless Integration and Customization

What sets Veeva AI Agents apart is their ability to operate seamlessly within the Veeva ecosystem, maintaining secure access to critical data, documents, and workflows while adhering to user permissions and audit trails. Moreover, customers have the flexibility to configure and extend Veeva's AI capabilities, creating custom agents tailored to their specific needs.

In addition, Veeva Business Consulting is available to help companies navigate the design and management of new business processes as they integrate these innovative AI solutions. This support is essential for maximizing the potential of AI within organizational workflows.

Community Response to Veeva AI

The release of Veeva AI has garnered positive feedback from industry leaders:

"By embedding AI into every step of the customer journey, Veeva AI supports us in our mission to provide life-changing medicines globally," commented Greg Meyers, Executive Vice President, Chief Digital and Technology Officer at Bristol Myers Squibb.

Jason Benagh from Moderna noted, "The Veeva AI Quick Check Agent brings us closer to a nearly touch-free MLR process, showing us the future of efficiency." Frank Armenante from Novo Nordisk emphasized that Veeva AI will allow teams to concentrate on the aspects of their roles that add the most value, benefitting businesses, healthcare providers (HCPs), and patients alike.

Debbie Young from Otsuka Europe highlighted the importance of Veeva AI in their ongoing transformation, while Kea Lingo from Crinetics expressed enthusiasm about leveraging the Free Text Agent for deeper customer insights.

Accenture's Craig Robertson remarked on the potential for Veeva AI to significantly boost productivity through its unique industry-focused approach. Silvano Perrotta from Ernst & Young shared similar sentiments, asserting that the Free Text and Voice Agents will ultimately transform commercial team operations.

About Veeva Systems

Veeva Systems is dedicated to providing the cloud infrastructure tailored for life sciences, delivering software solutions, data, and consulting services that are pivotal to industry success. With a client base exceeding 1,500, including the largest biopharmaceutical firms and emerging biotechs, Veeva is committed to innovation, product excellence, and customer satisfaction. As a Public Benefit Corporation, Veeva aims to balance the interests of all stakeholders, including customers and shareholders.

Frequently Asked Questions

What are Veeva AI Agents?

Veeva AI Agents are industry-specific AI tools designed to enhance productivity and customer engagement within life sciences applications.

How do Veeva AI Agents benefit the life sciences industry?

These agents improve the accuracy of data, streamline processes, and provide insightful analytics to help teams work more efficiently and effectively.

Which applications currently support Veeva AI?

Veeva AI Agents are currently available for Vault CRM and PromoMats, with future expansions planned for clinical, regulatory, and commercial applications.

Can customers customize Veeva AI Agents?

Yes, customers can configure and extend the capabilities of Veeva-delivered AI Agents, allowing for tailored solutions to fit their unique business needs.

How does Veeva support organizations implementing AI solutions?

Veeva Business Consulting provides guidance on business process design and change management, ensuring successful integration of AI technologies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 176

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 85

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 230

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 108

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 77

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 131

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 155

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 205

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading

Top 5 Most Recently Viewed Articles

DallasNews Shareholders Urged to Support Merger Deal with Hearst

Updated Category News Views 101

Overview of the DallasNews and Hearst Merger DallasNews Corporation, the parent company of The Dallas Morning News, has proposed a significant merger with Hearst, a prominent media organization. This merger offers an enticing cash value of $15.00 per share, bringing impressive benefits to shareholders. Recently, Glass Lewis, an independent proxy advisory firm, recommended...

Continue Reading
GitLab Director Karen Blasing's Recent Stock Transactions Explained

Updated Category News Views 154

Analyzing the Recent Insider Trading at GitLab GitLab Inc. (NASDAQ:GTLB) has recently drawn the attention of investors and market analysts due to stock transactions made by its director, Karen Blasing. A recent filing with the U.S. Securities and Exchange Commission revealed that Blasing sold a considerable amount of her stock holdings, totaling more than $173,000....

Continue Reading
Avenue Living's Strategic $350 Million Debenture Offering

Updated Category News Views 202

Avenue Living Announces $350 Million Senior Unsecured Debenture Offering Avenue Living (2014) LP has recently announced a significant financial move with a $350 million offering of Series B senior unsecured debentures. This opportunity is set to be priced at par and is due by September 25, 2028, indicating a long-term strategy for the company’s financing needs. Details...

Continue Reading
Fagron Reports Strong Financial Growth with Strategic Outlook

Updated Category News Views 349

Fagron's Remarkable Financial Performance Fagron, a global leader in pharmaceutical compounding, recently showcased its impressive results for the period ending December 31, 2024. The company’s financial achievements highlight significant growth across various sectors and regions in the pharmaceutical industry, reinforcing its commitment to excellence and innovation....

Continue Reading
Dizal's Sunvozertinib Receives Breakthrough Therapy Designation

Updated Category News Views 444

Dizal's Sunvozertinib Achieves Breakthrough Therapy Designation Dizal, a biopharmaceutical company dedicated to developing innovative cancer and immunological therapies, recently announced an important milestone. The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for sunvozertinib, aimed at...

Continue Reading